Search Orphan Drug Designations and Approvals
-
| Generic Name: | a fusion protein comprised of genetically engineered human serine peptidase inhibitor and human immunoglobulin G1 Fc |
|---|---|
| Date Designated: | 12/21/2022 |
| Orphan Designation: | Treatment of Netherton Syndrome |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Daiichi Sankyo, Inc. 211 Mount Airy Road Basking Ridge, New Jersey 07920 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







